Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). - Wikidata - wikimedia - TriplyDB

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

http://www.wikidata.org/entity/Q30662421

about

Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.Duration of antimicrobial therapy in community acquired pneumonia: less is more Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model Telithromycin in lower respiratory tract infections.Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia The emerging role of atypical pathogens in community-acquired pneumonia.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects.Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis.Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages.Factors affecting gentamicin penetration in lower extremity ischemic tissues with ulcers.

P2860

Q24813259-D1A6EA39-DCDD-4526-B9DC-184D2E8DAC9F Q26828493-CF5AED0E-1213-4EBF-872B-F2640608006F Q33555366-127AE84B-849F-4BCB-BB72-3762C19DCE31 Q36895727-34713AAF-16D4-4019-8E90-19ACBBAF3B3B Q36936597-2C3A922F-6C78-47B2-8CBE-D133EF18BFE1 Q37116814-8C4ECC75-01D0-4A98-B3E0-FB5C5607FCC5 Q37872805-7CBB0AE5-174E-4301-887E-18737641E7BF Q37927017-5B76C481-E113-4928-8738-91927AA740EC Q39390126-D469BEE4-4AA9-4951-866D-3D62B9BDCD02 Q40140019-1B8D3496-B314-4149-99E5-FD2FC450065B Q42252396-A4005867-AA0A-4D66-8AAC-397CBEC3A654 Q44518070-368C0194-FCA9-4E02-8FE9-16DE5A85E007 Q51100124-7F0A88D1-2755-407B-A54C-B49770A0A3D3 Q51423932-AC15EDE2-7814-4398-8383-D4FBFAFC5EA1

P2860

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

http://www.wikidata.org/entity/Q30662421

description

2001 nî lūn-bûn

@nan

2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

@ast

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

@en

type

label

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

@ast

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

@en

prefLabel

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

@ast

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

@en

P1433

Q30662421-831E704B-643C-4C55-AAF0-7F7274A4C228

P1476

Q30662421-357CB544-EE19-46A1-9A24-D469A854B4DC

P2093

Q30662421-0356E9C2-BD6A-43A9-BC4B-4D62B49B315A

Q30662421-2E8A96D1-F473-4AEA-B26B-9BAA6A34FA4E

Q30662421-31F2F5B4-6A72-49D7-8915-0D43821F6060

Q30662421-66CBAF88-0391-45A7-B53E-7AA3B23844DA

Q30662421-69C84ABE-A003-438A-A80C-74457FF116BF

Q30662421-94804ECA-7745-434B-855B-E28AA9A6BD33

Q30662421-BBBCCD5D-0BCF-4D52-A591-BC88068FF032

P2860

Q30662421-072004A1-8AFD-49D8-9AD8-9D3EFA40961C

Q30662421-1689A225-004B-4CCD-AA30-953E3C6F38ED

Q30662421-1769D65E-0BC4-40B6-962D-B5100BE1BC70

Q30662421-181B0947-D8DC-4530-8ECD-04C6989FD7EE

Q30662421-343013CE-312B-4007-A21C-45987FFBE5BD

Q30662421-353D526D-3CB2-4EBB-90F4-5CE3C60A1590

Q30662421-48C1E08D-749A-4165-8EE7-124D8CBAE993

Q30662421-4A66103C-C7E7-4ECA-83A5-A1F55183FAE4

Q30662421-5E5C1BD3-0838-4F6F-9A46-E180D512BF81

Q30662421-6F07739A-8FDE-409C-B221-78E2A505689F

P304

Q30662421-341DD23C-4A65-484E-A31E-36C3CB66C014

P31

Q30662421-CFC2600F-E897-42DB-BEDB-AA64F4FECBDE

P356

Q30662421-537E1D43-B629-4196-90E2-1FE7C1A1D11F

P407

Q30662421-6D40DE48-4376-46F9-8760-2397E7411AFF

P433

Q30662421-FBE15929-4475-4049-B456-F4A193669049

P478

Q30662421-867ED763-45D1-442F-9683-DE00A50F5570

P577

Q30662421-9E00AC84-53F1-4F17-A726-4D8C6459257E

P698

Q30662421-A37D6813-EB0E-47D6-8C7B-FD044E8D0170

P932

Q30662421-4F04C8BD-B0B9-4FD6-8C97-E9F7F854D579

P356

AAC.45.11.3104-3108.2001

P1433

Antimicrobial Agents and Chemotherapy

P1476

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

@en

P2093

A Andremont

http://www.w3.org/2001/XMLSchema#string

C Cantalloube

http://www.w3.org/2001/XMLSchema#string

C Muller-Serieys

http://www.w3.org/2001/XMLSchema#string

F Brunner

http://www.w3.org/2001/XMLSchema#string

F Lemaitre

http://www.w3.org/2001/XMLSchema#string

H P Gia

http://www.w3.org/2001/XMLSchema#string

P Soler

http://www.w3.org/2001/XMLSchema#string

P2860

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents

Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).

In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany.

Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.

Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.

Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses

Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.

The pharmacokinetics of azithromycin and their clinical significance.

Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients

P304

3104-3108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.45.11.3104-3108.2001

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11600363

http://www.w3.org/2001/XMLSchema#string

P932

90789

http://www.w3.org/2001/XMLSchema#string